Filters

Pp-184 manufacturers

Filters

1 products found

pp-184

Capsules

Dossier type
CTD
Dossier status
Under development
Country of origin
Taiwan
GMP approvals
Taiwan
Comments
Indication: Metastatic pancreatic ductal adenocarcinoma (mPDAC) — first-line Clinical stage: Phase 3 — IND accepted December 2025; Phase 3 initiation imminent Modality: Small molecule (ubiquinone / terpenoid derivative) Mechanism / Target: Ubiquinone analogue; inhibits AMPK–mTOR pathway and KRAS-driven oncogenic signalling; reduces aerobic glycolysis and induces apoptosis in KRAS-mutated tumour cells Route / form: Oral capsule Differentiation: First-in-class ubiquinone derivative targeting KRAS-driven pancreatic cancer;
Manufacturer #39325
Listed biopharmaceutical company focused on discovery and development of innovative Rx therapeutics for oncology and serious diseases, alongside evidence-based OTC health supplement products. Advances proprietary drug candidates through global clinical development with engagement in major regulated markets. Operates within a leading biomedical science park environment.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.